FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | | 50,000,000 | 本 ...

智通财经APP讯，健倍苗苗(02161)发布公告，黄一伟先生将辞任公司行政总裁以追求其他事业发展机 会，自2026年4月30日起生效。董事会进一步宣布，公司执行董事兼董事会主席岑广业先生将获委任为 新行政总裁，自2026年4月30日起生效。 ...

格隆汇1月30日丨健倍苗苗(02161.HK)宣布，黄一伟将辞任公司行政总裁以追求其他事业发展机会，自 2026年4月30日起生效。公司执行董事兼董事会主席岑广业将获委任为新行政总裁，自2026年4月30日起 生效。 ...

健倍苗苗(02161)发布公告，黄一伟先生将辞任公司行政总裁以追求其他事业发展机会，自2026年4月30 日起生效。董事会进一步宣布，公司执行董事兼董事会主席岑广业先生将获委任为新行政总裁，自2026 年4月30日起生效。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 行政總裁辭任 健倍苗苗（保 健）有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）宣 佈，黃 一 偉 先 生（「黃先生」）將辭任本公司行政總裁（「行政總 裁」）以 追 求 其 他 事 業 發 展 機 會，自 二 零 二 六 年 四 月 三 十 日 起 生 效。 黃 先 生 已 確 認 彼 與 董 事 會 並 無 意 見 分 歧，亦 概 無 有 關 彼 辭 任 的 事 宜 需 提 請 本 公司股東（「股 東」）及香港聯合交易所有限公司（「聯交所」）垂 注。 董 事 會 謹 藉 此 機 會 感 謝 黃 先 生 於 在 任 期 間 為 本 公 司 所 作 出 的 貢 獻。 委任新行政總裁 董 事 會 進 一 步 宣 佈，本 公 司 執 行 董 事 兼 董 事 會 主 席（「主 席」）岑廣業先生（「岑 ...

香港联交所最新资料显示，1月20日，主席岑广业减持健倍苗苗(02161)430万股，每股作价2.8港元，总 金额为1204万港元。减持后最新持股数目约为5.89亿股，最新持股比例为71.62%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | ...

NOTIFICATION LETTER 通知信函 12 December 2025 Dear Non-registered Shareholder(s)(Note 1), JBM (Healthcare) Limited (the "Company") – Notice of publication of 2025/2026 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.jbmhealthcare.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recomme ...

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：2161) NOTIFICATION LETTER 通知信函 12 December 2025 Dear Registered Shareholder(s), JBM (Healthcare) Limited (the "Company") – Notice of publication of 2025/2026 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.jbmhealthcare.com.hk and th ...

Financial Performance - Total revenue for the six months ended September 30, 2025, was HKD 429,644,000, representing a 7.7% increase from HKD 398,953,000 in the same period of 2024[9]. - Gross profit rose by 23.2% to HKD 253,601,000, with a gross margin of 59.0%, up from 51.6%[9]. - Profit attributable to equity holders increased by 20.0% to HKD 115,011,000, with a profit margin of 26.8%[9]. - Adjusted EBITDA for the period was HKD 175,315,000, reflecting a 21.7% increase, with an adjusted EBITDA margin of 40.8%[9][10]. - Operating profit rose by HKD 29.0 million or 23.8% to HKD 150.6 million, mainly due to increased gross profit[56]. - Net profit for the period was HKD 120,659,000, up 21.6% from HKD 99,276,000 in the same period last year[117]. - Basic and diluted earnings per share increased to HKD 14.12, compared to HKD 11.63 in the previous year, reflecting a growth of 21.4%[117]. - The company reported a total comprehensive income of HKD 120,962,000, an increase of 27.3% from HKD 95,027,000 in the prior year[117]. Revenue Breakdown - Brand medicine revenue increased by 15.5% to HKD 150,908,000, while health supplements revenue decreased by 13.2% to HKD 42,178,000[9]. - The brand health business recorded a revenue increase of 7.7% year-on-year to HKD 429.6 million, with gross profit rising by 23.2% to HKD 253.6 million, and profit attributable to equity holders increasing by 20.0% to HKD 115.0 million[24]. - The brand pharmaceutical segment, particularly the product He Ji Gong, achieved a revenue growth of 15.5% to HKD 150.9 million, driven by effective market strategies and promotional activities[27]. - Revenue from the traditional Chinese medicine segment increased by HKD 16.8 million, representing a growth of 7.6%, supported by strong sales of specific products[46]. - Revenue from external customers in Hong Kong increased significantly to HKD 367,443,000 in 2025 from HKD 264,631,000 in 2024, marking a growth of approximately 38.9%[138]. Assets and Liabilities - Total assets as of September 30, 2025, were HKD 1,771,878,000, a 14.7% increase from the previous period[9]. - Total liabilities increased by 67.9% to HKD 640,098,000, indicating a significant rise in financial obligations[9]. - Total equity decreased by 2.8% to HKD 1,131,780,000, suggesting a slight reduction in shareholder value[9]. - The net capital debt ratio as of September 30, 2025, was 13.8%, up from zero on March 31, 2025[71]. - Cash and cash equivalents decreased to HKD 194,197,000 as of September 30, 2025, from HKD 205,847,000 as of March 31, 2025, a decline of about 5.4%[120]. Strategic Initiatives - The company aims to enhance its brand management and product portfolio to strengthen its position in the Asian healthcare market[15]. - The company is committed to maintaining high-quality standards and is one of the few GMP-certified manufacturers of traditional Chinese medicine in Hong Kong[18]. - The company is leveraging its strong product portfolio and brand management expertise to navigate market challenges and enhance its position in the health product sector in Hong Kong and the Greater Bay Area[23]. - The company plans to expand its product portfolio by launching new concentrated Chinese medicine granules and health supplements, while also enhancing the registration scope of its compound granules[39]. - The company is set to launch an upgraded Chinese medicine e-commerce platform designed for practitioners and clinics to improve service efficiency and deepen customer interaction[39]. Marketing and Brand Development - The introduction of a new convenient packaging for Bao Ji Wan, designed for on-the-go consumption, is part of a comprehensive advertising campaign to boost brand visibility[30]. - The company is actively engaging in multi-channel marketing strategies to strengthen brand awareness and consumer interaction across different age groups[31]. - The brand's innovative marketing strategy won two industry awards in 2025, further solidifying its image in the pain relief category[33]. Acquisitions and Investments - The company completed the acquisition of 90% of Tianxi Tang's issued shares for a total consideration of HKD 171 million on April 3, 2025[75]. - The company also agreed to acquire all issued shares of Jianfu Tang Chinese Medicine Group for HKD 38 million on June 16, 2025[75]. - Tianxi Tang contributed revenue of HKD 12,800,000 and profit of HKD 5,335,000 from April 3, 2025, to September 30, 2025[160]. - Jianfu Tang contributed revenue of HKD 11,151,000 and profit of HKD 708,000 from June 30, 2025, to September 30, 2025[165]. Shareholder Information - The interim dividend declared for the six months ending September 30, 2025, is HKD 0.0975 per share, totaling approximately HKD 80.1 million, compared to HKD 0.055 per share and HKD 45.2 million for the same period last year[90]. - The major shareholder, Mr. Chan, holds approximately 71.96% of the issued share capital, equating to 591,523,346 shares[92]. - Lincoln's Hill holds 322,834,578 shares, representing 39.27% of the issued share capital[97]. - The company will suspend the transfer of shares from December 2 to December 3, 2025, to determine the eligibility of shareholders for the interim dividend[91]. Management and Governance - The audit committee consists of three independent non-executive directors, responsible for overseeing the integrity and accuracy of the company's financial statements[87]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[88]. - The company has no significant changes in the interests of directors and key executives in shares or related securities as of September 30, 2025[96].